Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma
NCT ID: NCT07030400
Last Updated: 2025-10-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
100 participants
OBSERVATIONAL
2025-06-05
2028-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
MEOI and HRQoL in CLL Patients Treated With BTKis
NCT04938141
Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
NCT03045120
Cardiotoxicities in Patients Receiving BTKi
NCT05521178
Ibrutinib as Early Therapy in Chronic Lymphocytic Leukemia (CLL)
NCT03207555
Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)
NCT00759798
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bruton's tyrosine kinase inhibitor treatment
Patients treated with a Bruton's tyrosine kinase inhibitor.
Bruton's tyrosine kinase inhibitor
BTKi
B-Cell Lymphoma 2 Protein Inhibitor treatment
Patients treated with a B-Cell Lymphoma 2 Protein Inhibitor.
B-Cell Lymphoma 2 Protein Inhibitor
BCL2i
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bruton's tyrosine kinase inhibitor
BTKi
B-Cell Lymphoma 2 Protein Inhibitor
BCL2i
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects must be able to read and speak English or Spanish at the 8th grade level.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Comprehensive Cancer Network
NETWORK
AstraZeneca
INDUSTRY
H. Lee Moffitt Cancer Center and Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sara Tinsley-Vance, PhD, APRN, AOCN
Role: PRINCIPAL_INVESTIGATOR
Moffitt Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Moffitt Cancer Center
Tampa, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MCC-23558
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.